25 September 2020 in Frontiers in Pharmacology
Chronic glomerulonephritis (CGN) as the culprit of kidney failure can increase the mortality of critically ill patients and seriously threatens people’s health all over the world. This study using metabolomics strategy is to reveal the potential therapeutic mechanism-related targets to evaluate the effects of rhein (RH) on CGN rats. Changes of serum metabolites and pathways were analyzed by non-targeted metabolomic method based on liquid chromatography-mass spectrometry (LC-MS) combined with ingenuity pathway analysis. In addition, the levels of biochemical indicators were also detected. A total of 25 potential biomarkers were identified to express serum metabolic turbulence in CGN animal model, and then 16 biomarkers were regulated by RH trending to the normal states. From metabolite enrichment and pathway analysis, pharmacological activity of RH on CGN were mainly involved in six vital metabolic pathways including phenylalanine, tyrosine and tryptophan biosynthesis, phenylalanine metabolism, arachidonic acid metabolism, tricarboxylic acid cycle (TCA cycle), alanine, aspartate, and glutamate metabolism, arginine and proline metabolism. It suggested CGN treatment with RH, which may be mediated via interference with metabolic pathway such as amino acid metabolism, arachidonic acid metabolism, and TCA cycle to regulating inflammation, oxidation response and immune regulation against CGN. It showed that metabolomics method offer deeply insight into the therapeutic mechanisms of natural product.
12 June 2023 in CNS Neuroscience & Therapeutics
Aims: Glioblastoma multiforme (GBM) is the deadliest glioma and its resistance to temozolomide (TMZ) remains intractable. Long non‐coding RNAs (lncRNAs) play crucial roles in that and this study aimed to investigate underlying mechanism of HOXD‐AS2‐affected temozolomide sensitivity in glioblastoma.Methods: We analyzed and validated the aberrant HOXD‐AS2 expression in glioma specimens. Then we explored the function of HOXD‐AS2 in vivo and in vitro and a clinical case was also reviewed to examine our findings. We further performed mechanistic experiments to investigate the mechanism of HOXD‐AS2 in regulating TMZ sensitivity.Results: Elevated HOXD‐AS2 expression promoted progression and negatively correlated with prognosis of glioma; HOXD‐AS2 attenuated temozolomide sensitivity in vitro and in vivo; The clinical case also showed that lower HOXD‐AS2 sensitized glioblastoma to temozolomide; STAT3‐induced HOXD‐AS2 could interact with IGF2BP2 protein to form a complex and sequentially upregulate STAT3 signaling, thus forming a positive feedback loop regulating TMZ sensitivity in glioblastoma.Conclusion: Our study elucidated the crucial role of the HOXD‐AS2‐STAT3 positive feedback loop in regulating TMZ sensitivity, suggesting that this could be provided as a potential therapeutic candidate of glioblastoma.
1 January 2026 in Translational Breast Cancer Research
Breast cancer is the most common form of cancer among women, and PSEN1 dysfunction is a primary contributor to the pathogenesis of Alzheimer’s disease. However, the involvement of PSEN1 in breast cancer remains unclear. This study was conducted to explore the function and related mechanisms of PSEN1 in breast cancer cells. The correlation between two genes was determined utilizing the R2 platform, and the association between gene expression and prognosis was analyzed employing the Kaplan-Meier plotter. The expression of PSEN1 in breast cancer was assessed by in immunofluorescence. The Transwell assay was employed to detect the migration and invasion capabilities of cells. Colony formation and EdU staining were employed to evaluate the effects of PSEN1 on breast cancer cell proliferation. We observed a positive correlation between the expression of PSEN1 and the prognosis of breast cancer patients. After manipulated the expression of PSEN1 in breast cancer cell lines Sum159 and BT549, we found that PSEN1 could inhibit cell proliferation and growth in breast cancer through colony formation assays and EdU staining. Meanwhile, we revealed that interference with the cell cycle by PSEN1 was associated with cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs) in breast cancer samples. Furthermore, we observed that an increase in PSEN1 expression inhibited the invasive capabilities of breast cancer cells, while a decrease in PSEN1 expression enhanced invasion in both Sum159 and BT549 cell lines. Lastly, we discovered a negative correlation between PSEN1 and epithelial-to-mesenchymal transition (EMT) transcription factors as well as markers in breast cancer patients. Our study demonstrates that PSEN1 inhibits the invasion and proliferation of breast cancer cells, suggesting that PSEN1 could potentially serve as a prognostic biomarker and a novel therapeutic target for patients with breast cancer.